cgrp blocker
Treatment for Cluster Headache
CGRP blockers, such as monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, work by preventing CGRP from binding to its receptor, thereby reducing neurogenic inflammation and vasodilation associated with cluster headaches. These medications inhibit the release of pro-inflammatory neuropeptides, effectively reducing the frequency, intensity, and duration of cluster headache attacks by modulating pain signaling pathways in the trigeminal system.